Researchers at the University of South Australia have developed a long-acting weekly injection for Parkinson’s disease that could replace multiple daily pills, potentially transforming treatment for millions worldwide.
Parkinson’s affects over 10 million people globally and is the second-most common neurodegenerative disease after Alzheimer’s. Current treatments require patients to take medications, such as Levodopa and Carbidopa, several times a day — a regimen that can be difficult to follow, particularly for elderly patients. Missing even a single dose can significantly impact daily functioning.
The newly developed injection combines Levodopa and Carbidopa into a single weekly dose, releasing medication steadily over seven days. This could improve adherence, reduce fall risks, and allow patients to lead more active lives.
“Almost 50% of patients don’t take medicines as prescribed, especially for chronic illnesses,” said Professor Sanjay Garg, lead researcher. “One injection per week is far more convenient than three or four tablets a day.”
While human trials have not yet begun, animal testing is expected to start soon. Parkinson’s Australia has hailed the development as a “game-changer,” offering hope to those like Peter Willis, who currently takes medication four times daily to manage symptoms.